GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics PLC (LSE:SUMM) » Definitions » Growth Rank

Summit Therapeutics (LSE:SUMM) Growth Rank : 0 (As of May. 18, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Summit Therapeutics Growth Rank?

Summit Therapeutics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Summit Therapeutics Growth Rank Related Terms

Thank you for viewing the detailed overview of Summit Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Summit Therapeutics (LSE:SUMM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Summit Therapeutics PLC (LSE:SUMM) » Definitions » Growth Rank
Comparable Companies
CGON ARWR MLTX ACAD APGE ACLX MRUS JANX IDYA CLDX OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
SMMT:USA
Address
2882 Sand Hill Road, Suite 106, Menlo Park, CA, USA, 94025
Website
https://www.smmttx.com
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its lead CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.

Summit Therapeutics (LSE:SUMM) Headlines

No Headlines